Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

Fulcher, G. and Matthews, D.R. and Perkovic, V. and de Zeeuw, D. and Mahaffey, K.W. and Mathieu, C. and Woo, V. and Wysham, C. and Capuano, G. and Desai, M. and Shaw, W. and Vercruysse, F. and Meininger, G. and Neal, B. and CANVAS trial collaborative group and Ukraine: and Larin, Oleksandr and Panina, Svetlana and Popik, Galyna and Kovalenko, Svitlana and Voloshyna, Olena and Tseluyko, Vera and Gyrina, Olga and Vizir, Vadim and Barna, Olga and Dolzhenko, Maryna and Ignatenko, Grigoriy and Mostovoy, Yuriy and Korpachev, Vadim and Mankovskiy, Boris and Vatutin, Mykola (2016) Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 18 (1). pp. 82-91. ISSN 1462-8902 (Print), 1463-1326 (Online)

	Text ORIGINAL ARTICLE.pdf Download (447kB)
	Text dom12589-sup-0005-appendixs1.pdf Download (156kB)

Abstract

Aims: To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist]. Methods: CANVAS is a double-blind, placebo-controlled study that randomized participants to canagliflozin 100 or 300 mg or placebo added to routine therapy. The present post hoc analysis assessed the efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18. Results: Of the 4330 patients in CANVAS, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions in glycated haemoglobin (HbA1c) in patients taking DPP-4 inhibitors [-0.56% (95% confidence interval [CI]: -0.77, -0.35), and -0.75% (95% CI: -0.95, -0.54), respectively] and GLP-1 receptor agonists [-1.00% (95% CI: -1.35, -0.65), and -1.06% (95% CI: -1.43, -0.69), respectively]. Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Higher incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. The incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all events occurred in patients on background insulin or insulin secretagogues. Conclusions: In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition.

Item Type:	Article
Additional Information:	Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8. PMID: 26450639.
Uncontrolled Keywords:	canagliflozin; type 2 diabetes.
Subjects:	Diabetes Endocrinology
Divisions:	Departments > Department of Internal Medicine 3 (formerly - hospital therapy 2)
Depositing User:	Елена Шрамко
Date Deposited:	11 Oct 2022 12:41
Last Modified:	11 Oct 2022 12:41
URI:	http://repo.dma.dp.ua/id/eprint/7860

Actions (login required)

View Item